Drug Utilisation Studies in Pharmacovigilance

Introduction

Drug Utilisation Studies (DUS) are among the most important pharmacoepidemiological tools used throughout the medicinal product lifecycle. They provide systematic information regarding how medicines are prescribed, dispensed and used in routine clinical practice. Unlike clinical trials, which evaluate medicines under carefully controlled conditions, Drug Utilisation Studies describe real-world medicine use across diverse healthcare settings and patient populations.

Within pharmacovigilance, Drug Utilisation Studies contribute to understanding whether medicines are being used according to their authorised indications, identifying patterns of prescribing, evaluating adherence to risk minimisation measures and supporting the interpretation of safety signals. They also provide valuable evidence for Risk Management Plans, Post-Authorisation Safety Studies (PASS), benefit-risk assessments and regulatory decision-making.

Drug Utilisation Studies have evolved from simple descriptions of medicine consumption into sophisticated observational investigations capable of addressing complex questions relating to prescribing behaviour, patient characteristics, treatment pathways, healthcare resource utilisation and the effectiveness of risk minimisation measures.

This article provides a comprehensive overview of Drug Utilisation Studies, including their scientific principles, methodologies, regulatory framework, practical applications and role within modern pharmacovigilance systems.

Learning Objectives

After reading this article you should be able to:

• define Drug Utilisation Studies and distinguish them from other pharmacoepidemiological studies;
• explain the objectives and scientific principles of Drug Utilisation Studies;
• understand common study designs and data sources;
• describe how Drug Utilisation Studies support pharmacovigilance and risk management;
• explain the relationship between Drug Utilisation Studies, PASS and Risk Management Plans;
• understand the strengths and limitations of Drug Utilisation Studies;
• prepare for regulatory inspections involving Drug Utilisation Studies.

History and Evolution of Drug Utilisation Studies

Drug Utilisation Studies have developed over several decades in response to the growing need to understand how medicines are used outside the controlled environment of clinical trials. Although pre-authorisation clinical studies establish the efficacy and safety of medicinal products under carefully defined conditions, they provide limited information regarding prescribing patterns, medicine use and patient behaviour in routine clinical practice.

As healthcare systems expanded and the availability of electronic prescribing and healthcare databases increased, researchers recognised that understanding how medicines are actually prescribed, dispensed and used was essential for improving patient safety, evaluating therapeutic practice and supporting rational medicine use.

Drug utilisation research therefore evolved into a distinct scientific discipline within pharmacoepidemiology, combining epidemiological methods with clinical pharmacology, public health and healthcare research to investigate medicine use at the population level.

Today, Drug Utilisation Studies support regulatory decision-making, pharmacovigilance activities, healthcare policy, reimbursement decisions, clinical guideline implementation and medicine optimisation across healthcare systems worldwide.

What Is a Drug Utilisation Study?

A Drug Utilisation Study (DUS) is an observational investigation that systematically describes, measures or evaluates how medicinal products are prescribed, dispensed and used within defined populations under routine clinical practice.

Unlike interventional clinical studies, Drug Utilisation Studies do not assign treatments or influence clinical management. Instead, they observe existing patterns of medicine use to answer predefined scientific, regulatory or public health questions.

Drug Utilisation Studies may investigate:

• who receives a medicine;
• why it is prescribed;
• how it is prescribed;
• how long treatment continues;
• how medicines are used in routine practice;
• whether use is consistent with approved product information;
• how utilisation changes over time.

These studies provide important evidence regarding real-world medicine use that cannot be obtained from pre-authorisation clinical trials alone.

Why Drug Utilisation Studies Are Performed

Medicinal products are often used differently in routine clinical practice than they are during clinical development.

Differences may arise because of:

• broader patient populations;
• multiple comorbidities;
• concomitant medicines;
• varying prescribing practices;
• differences between healthcare systems;
• evolving clinical guidelines;
• off-label prescribing;
• patient adherence.

Drug Utilisation Studies provide objective evidence describing these patterns of medicine use and enable organisations to understand whether real-world utilisation aligns with regulatory expectations and clinical practice.

Within pharmacovigilance, this information supports the interpretation of safety data and the evaluation of benefit-risk throughout the medicinal product lifecycle.

Scientific Principles of Drug Utilisation Studies

Drug Utilisation Studies are founded upon several important scientific principles.

First, medicine use should be measured systematically using predefined methods that allow meaningful interpretation and comparison.

Second, utilisation should be evaluated within the clinical context in which prescribing occurs rather than as isolated numerical measures.

Third, study design should be appropriate for the scientific question being addressed.

Finally, interpretation should recognise that medicine utilisation reflects interactions between patients, healthcare professionals, healthcare systems, regulatory requirements and clinical practice.

These principles distinguish rigorous pharmacoepidemiological research from simple descriptions of prescription volume or medicine sales.

Drug Utilisation Studies Within Pharmacoepidemiology

Drug Utilisation Studies represent one of the principal methodological approaches used within pharmacoepidemiology.

Where pharmacoepidemiology investigates the use and effects of medicines in populations, Drug Utilisation Studies focus specifically on patterns of medicine use.

These studies frequently provide the foundation for subsequent investigations examining:

• medicine safety;
• medicine effectiveness;
• healthcare quality;
• prescribing behaviour;
• adherence to treatment guidelines;
• implementation of risk minimisation measures.

Drug Utilisation Studies therefore occupy a central position within the broader discipline of pharmacoepidemiology.

Scientific Foundation

Drug Utilisation Studies are systematic observational investigations that describe how medicines are prescribed, dispensed and used under routine clinical practice. By providing objective evidence regarding real-world medicine utilisation, they bridge the gap between clinical development and everyday healthcare, supporting pharmacovigilance, pharmacoepidemiology, regulatory science and evidence-based decision-making throughout the medicinal product lifecycle.

Drug Utilisation Studies Versus Drug Consumption Studies

Although the terms are sometimes used interchangeably, Drug Utilisation Studies and Drug Consumption Studies address different scientific questions.

Drug Consumption Studies primarily quantify the volume of medicines used within a defined population. They commonly measure medicine use using metrics such as the number of prescriptions, Defined Daily Doses (DDD), packages dispensed or medicines consumed over a specified period. These studies are particularly useful for monitoring medicine use at regional, national or international levels and for informing healthcare planning.

Drug Utilisation Studies extend beyond measuring medicine consumption. They investigate how medicines are prescribed, dispensed and used in routine clinical practice while examining the clinical, demographic and healthcare system factors that influence medicine use.

For example, a Drug Consumption Study may report that antibiotic use increased by 12% over one year. A Drug Utilisation Study would investigate which patients received the antibiotics, why they were prescribed, whether prescribing complied with clinical guidelines, how treatment varied between healthcare settings and whether prescribing patterns changed over time.

Drug Consumption Studies therefore represent one component of the broader field of Drug Utilisation Research.

Drug Utilisation Studies Versus Pharmacoepidemiology

Pharmacoepidemiology is the scientific discipline that studies the use and effects of medicines in large populations using epidemiological methods.

Drug Utilisation Studies represent one important methodological approach within pharmacoepidemiology, but they do not encompass the entire discipline.

Pharmacoepidemiology includes investigations such as:

• Drug Utilisation Studies;
• Post-Authorisation Safety Studies;
• Post-Authorisation Efficacy Studies;
• comparative effectiveness research;
• safety signal evaluation;
• medicine safety studies;
• benefit-risk assessments.

Drug Utilisation Studies focus specifically on patterns of medicine use, whereas pharmacoepidemiology addresses broader questions relating to medicine utilisation, effectiveness, safety and public health.

Drug Utilisation Studies should therefore be viewed as a specialised subset of pharmacoepidemiology.

Drug Utilisation Studies Versus Post-Authorisation Safety Studies

Drug Utilisation Studies and Post-Authorisation Safety Studies (PASS) frequently use similar observational methodologies, but they differ in their primary objectives.

Drug Utilisation Studies primarily describe how medicines are used under routine clinical practice.

Typical questions include:

• Who receives the medicine?
• Why is it prescribed?
• Is prescribing consistent with the authorised indication?
• How long is treatment continued?
• How do prescribing patterns vary across healthcare settings?

In contrast, PASS are designed primarily to investigate medicine safety following marketing authorisation.

Typical PASS questions include:

• Does a newly identified safety concern occur under routine clinical practice?
• Has the frequency of an adverse reaction changed?
• Are additional risk minimisation measures effective?
• Has the benefit-risk balance changed?

Drug Utilisation Studies may form part of a PASS when medicine utilisation information is required to interpret safety findings. However, many Drug Utilisation Studies are performed independently of PASS because their objectives relate to medicine use rather than medicine safety.

Drug Utilisation Studies Versus Clinical Trials

Clinical trials and Drug Utilisation Studies generate complementary evidence throughout the medicinal product lifecycle.

Clinical trials are interventional studies conducted under carefully controlled conditions to evaluate the efficacy and safety of medicinal products before or after marketing authorisation.

Drug Utilisation Studies are observational investigations that describe medicine use under routine clinical practice without influencing treatment decisions.

Clinical trials typically involve:

• predefined eligibility criteria;
• protocol-driven treatment;
• controlled follow-up;
• selected patient populations.

Drug Utilisation Studies examine medicines as they are actually used within healthcare systems, including diverse patient populations, routine prescribing practices and variations in clinical care.

Consequently, Drug Utilisation Studies provide important real-world evidence that complements, rather than replaces, evidence obtained through clinical trials.

Why These Distinctions Matter

Understanding the differences between Drug Utilisation Studies and related scientific approaches is essential for selecting the most appropriate methodology to address a particular research question.

Choosing an inappropriate study design may result in data that are unable to answer the intended scientific or regulatory question.

For example:

• measuring prescription volume alone cannot determine whether prescribing complies with authorised indications;
• a Drug Utilisation Study cannot establish medicine efficacy in the manner of a randomised clinical trial;
• a PASS investigating medicine safety may require Drug Utilisation Study data to place safety findings into their appropriate clinical context.

Experienced pharmacovigilance professionals therefore begin with the research question before selecting the most appropriate study design.

Scientific Foundation

Drug Utilisation Studies are observational investigations that focus on patterns of medicine use in routine clinical practice. Although they contribute to pharmacoepidemiology and may support Post-Authorisation Safety Studies, they remain scientifically distinct from Drug Consumption Studies, clinical trials and other observational research because their primary objective is to characterise how medicines are prescribed, dispensed and used within real-world healthcare systems.

Regulatory Framework for Drug Utilisation Studies

Drug Utilisation Studies occupy an important position within the European pharmacovigilance framework because they provide objective evidence describing how medicinal products are used under routine clinical practice. Regulatory authorities use these studies to understand prescribing patterns, evaluate adherence to authorised conditions of use, assess the implementation of risk minimisation measures and support benefit-risk evaluation throughout the medicinal product lifecycle.

Unlike routine pharmacovigilance activities that primarily detect and evaluate adverse reactions, Drug Utilisation Studies characterise medicine use within healthcare systems. This information provides essential context for interpreting safety data and determining whether medicinal products are being used as intended.

Drug Utilisation Studies may therefore support regulatory decision-making before marketing authorisation, during post-authorisation surveillance and throughout ongoing lifecycle management.

Regulatory Objectives

Regulators may request or evaluate Drug Utilisation Studies to answer important questions regarding medicine use that cannot be addressed through spontaneous adverse event reporting alone.

Typical objectives include:

• describing prescribing patterns;
• identifying the populations receiving treatment;
• evaluating adherence to authorised indications;
• assessing implementation of risk minimisation measures;
• characterising off-label use;
• supporting interpretation of pharmacovigilance data;
• informing benefit-risk assessments.

The specific objectives should always be clearly defined before the study begins.

Drug Utilisation Studies Within the European Pharmacovigilance System

Within the European Union, Drug Utilisation Studies contribute to several pharmacovigilance activities.

These include:

• Risk Management Plans;
• Post-Authorisation Safety Studies;
• effectiveness evaluation of risk minimisation measures;
• benefit-risk assessment;
• signal evaluation;
• periodic safety reporting;
• regulatory referrals.

Although the role of a Drug Utilisation Study differs depending upon the regulatory question, its primary purpose remains the systematic evaluation of medicine use in routine clinical practice.

Relationship with GVP Module V

Good Pharmacovigilance Practices (GVP) Module V describes the principles governing Risk Management Systems.

Drug Utilisation Studies may be included within a Risk Management Plan when additional information regarding medicine utilisation is required to:

• characterise exposure;
• evaluate important identified or potential risks;
• understand prescribing behaviour;
• assess the implementation of risk minimisation measures.

Within the Risk Management Plan, the objectives, methodology and anticipated contribution of the Drug Utilisation Study should be clearly described.

Relationship with GVP Module VIII

GVP Module VIII provides guidance on Post-Authorisation Safety Studies.

Drug Utilisation Studies may be conducted as independent investigations or incorporated within PASS where information regarding medicine utilisation is necessary to address the study objectives.

Examples include:

• characterising the exposed population;
• estimating medicine utilisation;
• interpreting safety findings;
• evaluating changes in prescribing following regulatory action.

When conducted as part of a PASS, the Drug Utilisation Study should follow the scientific objectives and governance applicable to the overall study.

Relationship with GVP Module XVI

GVP Module XVI addresses the selection and evaluation of risk minimisation measures.

Drug Utilisation Studies frequently support the evaluation of both routine and additional risk minimisation measures by examining whether medicines are being prescribed and used according to programme requirements.

Examples include evaluating:

• restricted prescribing;
• adherence to authorised indications;
• implementation of Pregnancy Prevention Programmes;
• changes in prescribing following educational interventions;
• healthcare professional compliance with prescribing conditions.

Drug Utilisation Studies therefore provide important evidence regarding the implementation of regulatory risk minimisation strategies.

Drug Utilisation Studies and Risk Management Plans

Risk Management Plans frequently identify questions relating to medicine use that cannot be answered using spontaneous safety reports alone.

Drug Utilisation Studies may therefore be undertaken to:

• estimate patient exposure;
• identify populations at greatest risk;
• evaluate utilisation following regulatory action;
• characterise prescribing in special populations;
• support effectiveness evaluation of additional risk minimisation measures.

Findings may influence future revisions of the Risk Management Plan as new evidence becomes available.

Drug Utilisation Studies and Regulatory Commitments

In some circumstances, Drug Utilisation Studies form part of post-authorisation regulatory commitments.

Such studies may be requested when regulators require additional information regarding:

• patterns of medicine use;
• implementation of risk minimisation measures;
• prescribing behaviour;
• medicine exposure in specific populations;
• changes following regulatory interventions.

Study objectives, timelines and reporting requirements should be agreed with the relevant regulatory authorities where applicable.

Contribution to Regulatory Decision-Making

Drug Utilisation Study findings contribute to regulatory decisions throughout the medicinal product lifecycle.

Examples include:

• updating product information;
• revising Risk Management Plans;
• modifying risk minimisation measures;
• supporting referral procedures;
• informing benefit-risk assessments;
• identifying the need for further pharmacoepidemiological investigations.

The value of Drug Utilisation Studies lies not only in describing medicine use but also in providing evidence that supports informed regulatory action.

A Regulatory Tool for Understanding Real-World Medicine Use

Regulators increasingly recognise that understanding how medicines are used in routine clinical practice is essential for interpreting safety information and maintaining an appropriate benefit-risk balance.

Drug Utilisation Studies therefore complement traditional pharmacovigilance activities by providing objective evidence regarding medicine exposure, prescribing behaviour and healthcare practice. When integrated with Risk Management Plans, PASS, benefit-risk evaluation and risk minimisation activities, they become an important component of modern regulatory science.

Regulatory Perspective

Drug Utilisation Studies provide regulators with structured evidence describing how medicinal products are prescribed, dispensed and used in routine clinical practice. Their integration with Risk Management Plans, Post-Authorisation Safety Studies, risk minimisation measures and benefit-risk evaluation enables evidence-based regulatory decision-making throughout the medicinal product lifecycle while strengthening the overall pharmacovigilance system.

Common Objectives of Drug Utilisation Studies

Every Drug Utilisation Study begins with a clearly defined scientific, regulatory or public health question. Although these studies share common observational methodologies, their objectives vary considerably depending upon the medicinal product, the stage of the product lifecycle and the regulatory decisions they are intended to support.

Clearly defining the study objective is one of the most important stages of study planning because it determines the study design, data source, study population, variables, analytical methods and interpretation of the results.

Describing Medicine Utilisation

One of the fundamental objectives of Drug Utilisation Studies is to describe how medicines are used in routine clinical practice.

Typical questions include:

• How many patients receive the medicine?
• Which healthcare professionals prescribe it?
• Which healthcare settings use the medicine?
• How has utilisation changed over time?
• How does utilisation differ between countries or regions?

These descriptive studies establish the foundation for more detailed investigations.

Characterising the Treated Population

Drug Utilisation Studies frequently examine the characteristics of patients receiving a medicinal product.

Examples include:

• age distribution;
• sex distribution;
• underlying diseases;
• disease severity;
• relevant comorbidities;
• concomitant medicines;
• special populations.

Understanding the treated population is essential for interpreting both utilisation patterns and pharmacovigilance findings.

Evaluating Prescribing Behaviour

Prescribing behaviour is influenced by clinical evidence, treatment guidelines, regulatory actions, reimbursement policies and local healthcare practices.

Drug Utilisation Studies may investigate:

• prescribing preferences;
• physician specialties;
• initiation of therapy;
• treatment sequencing;
• medicine switching;
• dose escalation;
• dose reduction;
• discontinuation patterns.

These studies help explain how prescribing evolves under routine clinical practice.

Assessing Adherence to Authorised Use

Regulators often require evidence regarding whether medicines are being prescribed according to their approved conditions of use.

Drug Utilisation Studies may evaluate:

• authorised indications;
• approved patient populations;
• recommended dosing;
• duration of treatment;
• contraindications;
• restricted prescribing conditions.

Such studies support regulatory oversight and may identify opportunities to improve medicine use.

Identifying Off-Label Use

Drug Utilisation Studies are frequently used to characterise off-label prescribing.

Examples include use outside the:

• authorised indication;
• approved age group;
• recommended dose;
• specified route of administration;
• approved treatment duration.

Understanding off-label use assists organisations in interpreting safety information and planning further pharmacovigilance activities where appropriate.

Measuring Medicine Exposure

Accurate estimation of medicine exposure is fundamental to many pharmacovigilance activities.

Drug Utilisation Studies may estimate:

• numbers of exposed patients;
• cumulative exposure;
• treatment duration;
• treatment persistence;
• medicine utilisation over time;
• exposure within specific populations.

Exposure estimates frequently provide the denominator required for interpreting safety data.

Evaluating Risk Minimisation Measures

Drug Utilisation Studies play an important role in evaluating routine and additional risk minimisation measures.

Examples include assessing:

• prescribing restrictions;
• educational interventions;
• Pregnancy Prevention Programmes;
• controlled access programmes;
• implementation of regulatory recommendations;
• changes following Direct Healthcare Professional Communications (DHPCs).

These studies help determine whether regulatory interventions have influenced clinical practice.

Supporting Benefit-Risk Assessment

Medicine utilisation influences the interpretation of safety information throughout the product lifecycle.

Drug Utilisation Studies contribute to benefit-risk assessment by providing information regarding:

• who receives treatment;
• patterns of exposure;
• changes in prescribing;
• utilisation within higher-risk populations;
• healthcare practice over time.

These findings provide important context when evaluating emerging safety concerns.

Supporting Healthcare Planning

Beyond pharmacovigilance, Drug Utilisation Studies contribute to healthcare planning and policy development.

Examples include:

• forecasting medicine demand;
• evaluating access to treatment;
• assessing implementation of clinical guidelines;
• identifying geographical variation;
• supporting reimbursement decisions;
• informing public health initiatives.

Consequently, Drug Utilisation Studies have applications extending beyond regulatory pharmacovigilance.

Generating New Research Questions

Drug Utilisation Studies frequently identify findings that require further investigation.

These may include:

• unexpected prescribing trends;
• changes in medicine utilisation;
• variation between healthcare systems;
• use in previously unrecognised populations;
• unexpected adherence patterns;
• emerging healthcare practices.

Such observations often lead to additional pharmacoepidemiological studies, PASS, effectiveness evaluations or regulatory review.

The Research Question Determines the Study

Although Drug Utilisation Studies employ diverse observational methodologies, they all begin with a clearly defined objective.

Experienced pharmacoepidemiologists first determine the question that requires an answer and only then select the most appropriate study design, data source and analytical approach.

This objective-driven approach ensures that Drug Utilisation Studies generate meaningful evidence capable of supporting clinical practice, pharmacovigilance activities and regulatory decision-making.

Scientific Foundation

Drug Utilisation Studies are objective-driven observational investigations designed to answer specific questions regarding medicine use in routine clinical practice. Their applications extend from describing medicine utilisation and evaluating prescribing behaviour to assessing risk minimisation measures, supporting benefit-risk assessment and informing regulatory and public health decisions throughout the medicinal product lifecycle.

Study Designs Used in Drug Utilisation Studies

Drug Utilisation Studies employ a wide range of observational study designs depending upon the scientific question, available data sources and regulatory objectives. Unlike clinical trials, which follow predefined intervention protocols, Drug Utilisation Studies observe medicine use as it occurs naturally within routine healthcare systems.

No single study design is suitable for every research question. The choice of methodology should be guided by the study objective, characteristics of the study population, availability of data and the level of evidence required to support clinical, regulatory or public health decision-making.

Selecting an appropriate study design is therefore one of the most important stages of study planning.

Selecting the Appropriate Study Design

Experienced pharmacoepidemiologists begin by defining the research question before selecting a study design.

Important considerations include:

• the primary study objective;
• the target population;
• the required follow-up period;
• availability of healthcare data;
• expected frequency of medicine use;
• feasibility of data collection;
• regulatory requirements;
• potential sources of bias.

The methodology should always be capable of answering the predefined research question.

Descriptive and Analytical Studies

Drug Utilisation Studies may broadly be divided into descriptive and analytical investigations.

Descriptive studies seek to characterise medicine use without formally comparing groups or testing hypotheses.

Typical objectives include:

• describing prescribing patterns;
• estimating medicine utilisation;
• characterising treated populations;
• monitoring changes over time.

Analytical studies evaluate relationships between variables and may compare utilisation between populations, healthcare settings or time periods.

Both approaches contribute valuable information depending upon the objectives of the investigation.

Cross-Sectional Studies

Cross-sectional studies examine medicine use at a single point in time or during a defined time period.

They are commonly used to:

• estimate medicine utilisation;
• describe prescribing practices;
• assess adherence to treatment guidelines;
• identify patient characteristics;
• evaluate healthcare utilisation.

Cross-sectional studies are relatively efficient and provide useful snapshots of prescribing behaviour but cannot establish temporal changes or treatment trajectories.

Cohort Studies

Cohort studies follow defined groups of patients over time to evaluate patterns of medicine use.

They may investigate:

• treatment initiation;
• duration of therapy;
• treatment persistence;
• medicine switching;
• dose modification;
• long-term utilisation patterns.

Cohort studies are particularly valuable when understanding how medicine use evolves throughout the patient journey.

Retrospective Studies

Retrospective Drug Utilisation Studies analyse existing healthcare data collected before the study begins.

Common data sources include:

• electronic health records;
• prescription databases;
• administrative claims databases;
• hospital information systems;
• pharmacy dispensing records.

Retrospective studies are generally efficient and cost-effective because the required information has already been collected during routine healthcare delivery.

Prospective Studies

Prospective Drug Utilisation Studies collect information after the study has commenced.

Patients or healthcare providers are followed according to a predefined study protocol.

Prospective designs may provide:

• more complete clinical information;
• standardised data collection;
• consistent variable definitions;
• improved data quality;
• greater flexibility in measuring study endpoints.

However, prospective studies often require greater time, resources and organisational coordination.

Longitudinal Studies

Longitudinal studies evaluate medicine utilisation repeatedly over extended periods.

These studies help investigators understand:

• changes in prescribing practice;
• adoption of new medicines;
• long-term treatment persistence;
• regulatory impact;
• changes following guideline updates;
• evolving healthcare practice.

Longitudinal analyses are particularly useful for evaluating trends throughout the medicinal product lifecycle.

Ecological Studies

Ecological studies analyse medicine utilisation at the population or healthcare system level rather than at the level of individual patients.

Examples include comparisons between:

• countries;
• regions;
• healthcare organisations;
• hospitals;
• primary care networks.

These studies are useful for identifying large-scale utilisation patterns but should not be used to infer individual patient behaviour.

Before-and-After Studies

Before-and-after studies compare medicine utilisation before and after a defined intervention.

Interventions may include:

• regulatory actions;
• implementation of risk minimisation measures;
• publication of new clinical guidelines;
• educational programmes;
• Direct Healthcare Professional Communications (DHPCs).

These studies help evaluate whether interventions influence prescribing behaviour under routine clinical practice.

Interrupted Time-Series Studies

Interrupted time-series studies evaluate medicine utilisation across multiple time points before and after an intervention.

Compared with simple before-and-after studies, interrupted time-series analyses provide a stronger assessment of whether observed changes are associated with a specific intervention rather than natural variation over time.

These studies are increasingly used to evaluate the impact of regulatory actions and public health interventions.

Hybrid Study Designs

Complex regulatory questions may require combinations of several study designs.

For example, investigators may combine:

• longitudinal cohort analyses;
• cross-sectional evaluations;
• interrupted time-series analyses;
• healthcare database studies.

Hybrid approaches allow researchers to address multiple complementary research questions within a single Drug Utilisation Study programme.

Choosing the Right Design

There is no universally superior Drug Utilisation Study design.

The most appropriate methodology depends upon:

• the scientific objective;
• regulatory expectations;
• available data;
• healthcare setting;
• study feasibility;
• potential sources of bias.

Experienced investigators recognise that methodological rigour begins with selecting a study design capable of answering the intended research question while acknowledging the strengths and limitations of the chosen approach.

Scientific Foundation

Drug Utilisation Studies employ a range of observational study designs, each suited to different scientific and regulatory questions. Selecting the appropriate methodology requires careful consideration of the study objectives, available data, healthcare context and potential biases. The strength of a Drug Utilisation Study depends not on the complexity of its design but on how well that design addresses the predefined research question.

Data Sources for Drug Utilisation Studies

The validity of a Drug Utilisation Study depends not only upon its study design but also upon the quality, completeness and suitability of the data source. Different healthcare databases capture different aspects of medicine use, and no single source provides a complete picture of prescribing, dispensing and patient utilisation.

Selecting an appropriate data source therefore represents one of the most important scientific decisions made during study planning. The choice should always be driven by the study objective rather than by database availability or convenience.

Principles of Data Source Selection

Before selecting a data source, investigators should consider whether it can reliably answer the predefined research question.

Important considerations include:

• completeness of medicine exposure data;
• availability of clinical diagnoses;
• patient follow-up duration;
• population representativeness;
• data accuracy;
• coding standards;
• timeliness of data availability;
• linkage with other healthcare datasets;
• legal and ethical considerations.

A large database is not necessarily a better database. Suitability for the research question is more important than database size.

Primary and Secondary Data Sources

Drug Utilisation Studies may use either primary or secondary data.

Primary data are collected specifically for the study and may include prospective patient enrolment, physician questionnaires or structured data collection forms.

Secondary data consist of information originally collected for clinical care, reimbursement, administrative or public health purposes and later analysed for research.

Most contemporary Drug Utilisation Studies use secondary healthcare databases because they provide access to large populations observed during routine clinical practice.

Electronic Health Records

Electronic Health Records (EHRs) are among the most valuable sources of information for Drug Utilisation Studies.

Depending on the healthcare system, they may include:

• diagnoses;
• prescribed medicines;
• laboratory results;
• clinical observations;
• comorbidities;
• treatment duration;
• clinical outcomes.

Because EHRs contain rich clinical information, they are particularly useful when medicine utilisation must be interpreted within the context of patient characteristics and disease severity.

However, prescribing records do not always confirm that medicines were dispensed or taken by the patient.

Administrative Claims Databases

Administrative claims databases are generated primarily to support healthcare reimbursement.

These databases commonly include:

• reimbursed prescriptions;
• healthcare encounters;
• hospital admissions;
• outpatient visits;
• medical procedures;
• diagnostic codes.

Claims databases often provide excellent longitudinal follow-up and large study populations, making them valuable for evaluating utilisation patterns over extended periods.

Their principal limitation is that clinical detail may be less comprehensive than in Electronic Health Records.

Pharmacy Dispensing Databases

Dispensing databases record medicines supplied by community or hospital pharmacies.

These databases are particularly useful for evaluating:

• dispensing frequency;
• refill behaviour;
• treatment persistence;
• medicine availability;
• dispensing trends.

Because dispensing confirms that a medicine was supplied, these databases may provide a more accurate estimate of medicine exposure than prescribing records alone.

Nevertheless, dispensing does not guarantee that the patient actually consumed the medicine.

Prescription Databases

Prescription databases capture medicines prescribed by healthcare professionals.

These databases support investigations examining:

• prescribing behaviour;
• physician preferences;
• medicine initiation;
• prescribing trends;
• compliance with authorised indications.

Prescription databases are especially valuable when evaluating the impact of regulatory interventions or changes in clinical guidelines.

Hospital Information Systems

Hospital databases provide detailed information regarding medicines used in secondary and tertiary care.

They may include:

• inpatient prescribing;
• infusion medicines;
• specialist treatments;
• discharge medicines;
• hospital diagnoses;
• procedural information.

Hospital information systems are particularly important for evaluating medicines that are predominantly administered in specialist healthcare settings.

Primary Care Databases

Many Drug Utilisation Studies are conducted using primary care databases because they reflect routine prescribing in the community.

These databases may provide information regarding:

• chronic medicine use;
• long-term prescribing;
• comorbidities;
• repeat prescriptions;
• treatment changes;
• referrals.

Primary care databases are especially useful for studying medicines commonly initiated or maintained outside hospital settings.

Disease and Product Registries

Disease registries and product-specific registries collect structured information relating to defined patient populations.

These registries often provide:

• confirmed diagnoses;
• disease severity;
• treatment history;
• medicine exposure;
• clinical outcomes;
• long-term follow-up.

Registry data are particularly valuable when studying uncommon diseases or medicines used in specialised clinical practice.

National Healthcare Databases

Several countries maintain national healthcare databases that integrate information from multiple healthcare settings.

Depending upon the healthcare system, these databases may combine:

• prescribing records;
• dispensing data;
• hospital admissions;
• mortality records;
• disease registries;
• laboratory information.

Integrated national databases allow investigators to examine medicine utilisation across large, representative populations.

Multi-Database Studies

Increasingly, Drug Utilisation Studies combine information from multiple databases.

Multi-database studies may improve:

• population representativeness;
• sample size;
• international comparisons;
• generalisability;
• evaluation of rare utilisation patterns.

However, combining databases introduces methodological challenges relating to coding systems, data harmonisation, variable definitions and analytical consistency.

Data Quality and Validation

The quality of study findings depends directly upon the quality of the underlying data.

Investigators should evaluate:

• completeness;
• accuracy;
• consistency;
• timeliness;
• validity;
• duplicate records;
• missing information;
• coding quality.

Where possible, validation studies should be undertaken to confirm that important variables accurately represent clinical practice.

Strengths and Limitations of Different Data Sources

Every data source has strengths and limitations.

For example:

• Electronic Health Records provide rich clinical detail but may not confirm medicine dispensing.
• Pharmacy databases confirm dispensing but cannot confirm medicine consumption.
• Claims databases support large population studies but may contain limited clinical information.
• Registries provide detailed disease-specific data but often include smaller populations.

Experienced investigators understand these limitations and interpret study findings accordingly.

Selecting the Right Data Source

There is no universally superior database for Drug Utilisation Studies.

Instead, investigators should select the data source—or combination of data sources—that best addresses the predefined research question while providing sufficient completeness, validity and representativeness.

Careful selection of data sources strengthens the scientific credibility of Drug Utilisation Studies and improves the reliability of the evidence used to support pharmacovigilance, regulatory decision-making and public health.

Scientific Foundation

Data source selection is a critical determinant of Drug Utilisation Study quality. Electronic Health Records, claims databases, dispensing records, prescription databases, hospital systems and disease registries each provide different perspectives on medicine use. Selecting the most appropriate data source requires balancing completeness, validity, representativeness and clinical relevance against the specific objectives of the study.

Drug Utilisation Metrics and Classification Systems

Drug Utilisation Studies require standardised methods for describing medicine use. Without common terminology and measurement systems, comparisons between healthcare providers, institutions, countries or time periods would be unreliable and potentially misleading.

To address this challenge, internationally recognised classification systems and utilisation metrics have been developed. These standards enable investigators to measure medicine utilisation consistently, compare findings across studies and interpret utilisation patterns within a common scientific framework.

The selection of an appropriate metric depends upon the research question. No single measure is suitable for every Drug Utilisation Study.

Why Standardised Metrics Are Needed

Medicines may be prescribed in different doses, strengths, formulations and treatment durations.

For example, the same medicine may be:

• initiated at different doses;
• titrated during treatment;
• prescribed for different indications;
• administered using different formulations;
• used for short-term or long-term therapy.

Simply counting prescriptions rarely reflects true medicine utilisation.

Standardised utilisation metrics allow investigators to compare medicine use despite these differences.

Anatomical Therapeutic Chemical (ATC) Classification System

The Anatomical Therapeutic Chemical (ATC) Classification System, maintained by the World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology, classifies medicines according to:

• anatomical group;
• therapeutic use;
• pharmacological class;
• chemical characteristics.

Each medicinal substance receives a unique ATC code, enabling consistent identification across countries and healthcare systems.

The ATC Classification System provides the foundation for international drug utilisation research by ensuring that medicines are classified using a common methodology.

Defined Daily Dose (DDD)

The Defined Daily Dose (DDD) is the assumed average maintenance dose per day for a medicine used for its principal indication in adults.

DDD is a technical unit of measurement rather than a recommended therapeutic dose.

Its primary applications include:

• comparing medicine utilisation between populations;
• monitoring utilisation trends over time;
• evaluating national prescribing patterns;
• supporting international comparisons.

Because DDD represents a standardised measurement rather than actual prescribing behaviour, it should not be interpreted as the appropriate dose for individual patients.

Prescribed Daily Dose (PDD)

The Prescribed Daily Dose (PDD) represents the average daily dose actually prescribed within a defined patient population.

Unlike DDD, which is standardised internationally, PDD reflects real-world prescribing behaviour.

Comparing PDD with DDD may identify:

• differences between routine prescribing and standard utilisation assumptions;
• regional prescribing variation;
• changes in clinical practice;
• utilisation within specific patient populations.

Interpretation should always consider the clinical context in which prescribing occurs.

Days of Therapy (DOT)

Days of Therapy (DOT) measures the number of days during which a patient receives a medicinal product, regardless of dose.

DOT is commonly used in:

• antimicrobial stewardship;
• hospital medicine utilisation studies;
• treatment duration analyses;
• healthcare quality improvement initiatives.

Unlike DDD, DOT reflects treatment duration rather than medicine quantity.

Days' Supply

Days' Supply estimates the number of days for which a dispensed prescription is expected to provide treatment.

This metric supports evaluation of:

• dispensing patterns;
• refill behaviour;
• medicine availability;
• treatment continuity.

Days' Supply is widely used in pharmacy databases and administrative claims analyses.

Medication Possession Ratio (MPR)

Medication Possession Ratio (MPR) estimates the proportion of time during which patients possess sufficient medicine based upon dispensing records.

MPR is frequently used to evaluate medicine adherence within chronic disease management.

Although widely used, MPR assumes that medicines supplied are consumed as prescribed and therefore cannot directly measure actual medicine intake.

Proportion of Days Covered (PDC)

Proportion of Days Covered (PDC) estimates the proportion of days during which patients have medicine available over a defined observation period.

Compared with MPR, PDC avoids double-counting overlapping prescriptions and is often preferred when evaluating long-term adherence.

Both MPR and PDC estimate medicine availability rather than confirmed medicine consumption.

Incidence and Prevalence of Medicine Use

Drug Utilisation Studies frequently distinguish between:

Incidence of use, describing new users of a medicine during a defined period.

Prevalence of use, describing all users of the medicine during that period, regardless of when treatment began.

These measures provide complementary information regarding medicine uptake and overall utilisation.

Treatment Persistence

Treatment persistence describes the duration of time from treatment initiation until discontinuation.

Persistence studies help investigators understand:

• continuation of therapy;
• treatment discontinuation;
• medicine switching;
• long-term treatment patterns.

Persistence differs from adherence because it focuses on treatment continuation rather than medicine-taking behaviour.

Treatment Adherence

Treatment adherence describes the extent to which medicine use corresponds with the agreed treatment regimen.

Drug Utilisation Studies may estimate adherence using dispensing records, prescription refill patterns or other indirect measures.

Because most observational databases cannot directly confirm medicine ingestion, adherence estimates should be interpreted cautiously.

Drug Switching

Drug switching analyses examine movement from one medicinal product to another.

Switching studies may investigate:

• therapeutic substitution;
• treatment escalation;
• treatment simplification;
• formulary changes;
• regulatory interventions.

These analyses provide valuable insight into prescribing behaviour and treatment pathways.

Dose Escalation and Dose Reduction

Many Drug Utilisation Studies evaluate changes in prescribed dose over time.

Dose analyses may identify:

• treatment optimisation;
• inadequate disease control;
• adverse reaction management;
• changes in clinical guidelines;
• real-world prescribing practices.

Dose modification patterns often provide important context for interpreting medicine utilisation.

Selecting the Appropriate Metric

The choice of utilisation metric should always reflect the study objective.

For example:

• DDD supports international comparisons.
• PDD describes real-world prescribing.
• DOT evaluates treatment duration.
• MPR and PDC estimate adherence.
• Incidence and prevalence describe medicine uptake.
• Persistence evaluates treatment continuation.

Experienced investigators avoid relying upon a single metric and instead select complementary measures that best address the predefined research question.

Scientific Foundation

Standardised classification systems and utilisation metrics enable Drug Utilisation Studies to measure medicine use consistently across populations and healthcare systems. The ATC Classification System, Defined Daily Dose, Prescribed Daily Dose, Days of Therapy, adherence measures and treatment persistence each describe different aspects of medicine utilisation. Appropriate metric selection is therefore essential for generating scientifically meaningful and internationally comparable evidence.

Study Variables, Endpoints and Analytical Methods

Drug Utilisation Studies require careful definition of study variables, endpoints and analytical methods before data collection or analysis begins. Clear definitions improve scientific validity, facilitate reproducibility and ensure that the study answers its intended research question.

A well-designed analytical plan should distinguish between variables describing medicine exposure, patient characteristics, healthcare utilisation and study outcomes. These definitions should be established prospectively and documented within the study protocol.

Defining Study Variables

A study variable is any measurable characteristic collected during the investigation.

Variables should be:

• clinically relevant;
• clearly defined;
• consistently measured;
• appropriate for the study objective;
• supported by the available data source.

Careful variable selection improves data quality and reduces ambiguity during analysis.

Exposure Variables

Exposure variables describe how patients receive the medicinal product.

Examples include:

• treatment initiation;
• prescribed medicine;
• dose;
• formulation;
• route of administration;
• treatment duration;
• cumulative exposure;
• treatment interruptions;
• switching between medicines.

Accurate exposure measurement is fundamental because all subsequent analyses depend upon reliable characterisation of medicine use.

Patient Variables

Patient variables describe the characteristics of individuals included in the study.

These commonly include:

• age;
• sex;
• diagnosis;
• disease severity;
• comorbidities;
• pregnancy status where relevant;
• renal or hepatic impairment;
• previous treatment history.

These variables help characterise the treated population and support interpretation of utilisation patterns.

Healthcare System Variables

Drug utilisation is influenced by the healthcare environment.

Studies may therefore collect information regarding:

• healthcare setting;
• prescriber specialty;
• country or region;
• reimbursement status;
• hospital versus community prescribing;
• formulary restrictions;
• regulatory interventions.

These variables help explain differences in medicine utilisation between healthcare systems.

Covariates

Covariates are variables that may influence the relationship between medicine utilisation and the study outcomes.

Examples include:

• age;
• sex;
• disease severity;
• concomitant medicines;
• socioeconomic factors;
• healthcare access;
• comorbid conditions.

Appropriate consideration of covariates improves the validity of study findings.

Confounding

Confounding occurs when an external factor influences both medicine utilisation and the outcome being studied, creating a misleading association.

For example, patients receiving a specialist medicine may differ systematically from those not receiving treatment because of disease severity, referral patterns or underlying health status.

Investigators should identify potential confounders during study planning and consider appropriate analytical methods to minimise their influence.

Effect Modification

Some variables may alter the relationship between medicine utilisation and the outcome of interest.

Examples include:

• age groups;
• sex;
• renal function;
• geographical region;
• healthcare setting.

Evaluating effect modification may reveal clinically important differences between patient subgroups that would otherwise remain unrecognised.

Primary and Secondary Endpoints

Every Drug Utilisation Study should define its primary endpoint before analysis begins.

The primary endpoint should directly address the principal research question.

Secondary endpoints may evaluate additional aspects of medicine utilisation, including:

• prescribing patterns;
• treatment persistence;
• dose modification;
• switching behaviour;
• adherence measures;
• healthcare utilisation.

Clearly distinguishing primary and secondary endpoints reduces the risk of selective reporting.

Numerators and Denominators

Meaningful interpretation of utilisation metrics requires clearly defined numerators and denominators.

Examples include:

• number of exposed patients;
• number of prescriptions;
• number of treatment episodes;
• population size;
• eligible patient population;
• person-time at risk.

Poorly defined denominators may produce misleading estimates of medicine utilisation.

Time at Risk

Many Drug Utilisation Studies evaluate medicine use over time.

The observation period should be clearly defined, including:

• treatment initiation;
• follow-up duration;
• treatment discontinuation;
• censoring events;
• study completion.

Consistent definition of the observation period improves comparability between studies.

Person-Time Measures

Some Drug Utilisation Studies express exposure using person-time measures such as person-years or person-months.

These measures account for differences in follow-up duration between patients and are particularly useful when comparing medicine utilisation across heterogeneous populations.

Person-time metrics also facilitate integration with pharmacoepidemiological and safety analyses.

Descriptive Statistical Analysis

Most Drug Utilisation Studies begin with descriptive statistical analyses.

These commonly include:

• frequencies;
• proportions;
• means;
• medians;
• standard deviations;
• interquartile ranges;
• incidence rates;
• prevalence estimates.

Descriptive analyses provide an overview of medicine utilisation before more detailed investigations are undertaken.

Comparative Analysis

Some Drug Utilisation Studies compare utilisation between different populations or time periods.

Comparisons may involve:

• geographical regions;
• healthcare settings;
• patient subgroups;
• pre- and post-regulatory interventions;
• different medicinal products.

The analytical methods selected should be appropriate for the predefined study objectives and the characteristics of the available data.

Missing Data

Missing information is common in observational healthcare databases.

Investigators should assess:

• the extent of missing data;
• potential reasons for missingness;
• the impact on study validity;
• appropriate methods for handling incomplete information.

Transparent reporting of missing data improves the credibility of study findings.

Sensitivity Analyses

Sensitivity analyses evaluate whether study conclusions remain consistent when alternative assumptions or analytical methods are applied.

Examples include:

• alternative exposure definitions;
• different follow-up periods;
• revised inclusion criteria;
• subgroup analyses;
• alternative statistical models.

Sensitivity analyses strengthen confidence in the robustness of the study findings.

Transparency and Reproducibility

The analytical methods used in a Drug Utilisation Study should be documented clearly within the study protocol and final study report.

Transparent reporting enables:

• independent scientific review;
• regulatory assessment;
• reproducibility;
• comparison with other studies;
• future meta-research.

Scientific transparency is a fundamental principle of high-quality pharmacoepidemiological research.

Scientific Foundation

Carefully defined variables, endpoints and analytical methods form the methodological foundation of every Drug Utilisation Study. Clear exposure definitions, appropriate covariate selection, meaningful endpoints and transparent analytical plans enable investigators to generate reliable evidence describing medicine utilisation while supporting pharmacovigilance, regulatory decision-making and public health.

Applications of Drug Utilisation Studies in Pharmacovigilance

Drug Utilisation Studies have become an integral component of modern pharmacovigilance because they provide objective evidence describing how medicines are used in routine clinical practice. Although they do not directly evaluate adverse reactions, they provide the essential context required to interpret safety data, evaluate risk minimisation measures and support regulatory decision-making.

Throughout the medicinal product lifecycle, Drug Utilisation Studies contribute to understanding who receives a medicine, how it is prescribed, whether it is used according to authorised conditions and how prescribing behaviour changes over time. This information complements spontaneous adverse event reporting, clinical studies and pharmacoepidemiological investigations.

Supporting Risk Management Plans

Drug Utilisation Studies frequently form part of Risk Management Plans when important questions exist regarding medicine use.

These studies may help to:

• characterise medicine exposure;
• identify treated patient populations;
• evaluate use in populations of special interest;
• assess adherence to approved indications;
• estimate exposure required for safety evaluations;
• support post-authorisation commitments.

Within a Risk Management Plan, Drug Utilisation Studies provide evidence that complements routine pharmacovigilance activities and supports the ongoing evaluation of important identified risks, important potential risks and missing information.

Supporting Signal Management

Safety signals cannot be interpreted without understanding medicine utilisation.

Drug Utilisation Studies provide important contextual information by describing:

• changes in medicine exposure;
• prescribing trends;
• utilisation in higher-risk populations;
• geographical variation;
• changes following regulatory actions.

For example, an increase in reported adverse reactions may reflect increased prescribing rather than an increased incidence of the reaction itself. Drug Utilisation Studies help distinguish these possibilities by providing reliable exposure information.

Supporting Benefit-Risk Assessment

Benefit-risk assessment requires an understanding of both medicine safety and medicine utilisation.

Drug Utilisation Studies contribute by describing:

• the populations receiving treatment;
• patterns of medicine exposure;
• treatment duration;
• utilisation in patients with contraindications;
• prescribing outside authorised conditions;
• changes in clinical practice over time.

These findings provide important context when reassessing the overall benefit-risk balance of a medicinal product.

Evaluating Risk Minimisation Measures

One of the most important applications of Drug Utilisation Studies is the evaluation of routine and additional risk minimisation measures.

These studies may examine whether regulatory interventions have resulted in:

• changes in prescribing behaviour;
• improved adherence to authorised indications;
• reduced prescribing in contraindicated populations;
• implementation of educational programmes;
• compliance with prescribing restrictions.

Drug Utilisation Studies therefore provide objective evidence regarding whether risk minimisation activities influence routine clinical practice.

Supporting Pregnancy Prevention Programmes

Pregnancy Prevention Programmes frequently require evidence demonstrating that programme requirements are implemented effectively.

Drug Utilisation Studies may evaluate:

• prescribing to patients of childbearing potential;
• adherence to prescribing restrictions;
• implementation of programme requirements;
• changes in prescribing following regulatory actions;
• utilisation before and after programme implementation.

These findings complement pregnancy exposure monitoring, pregnancy registries and effectiveness evaluations.

Supporting Post-Authorisation Safety Studies

Drug Utilisation Studies may be performed independently or incorporated within Post-Authorisation Safety Studies.

Within PASS, they may provide information regarding:

• medicine exposure;
• patient selection;
• prescribing behaviour;
• treatment pathways;
• interpretation of safety findings.

Utilisation data strengthen PASS by providing the clinical context necessary to interpret observed safety outcomes.

Supporting Periodic Safety Reports

Drug Utilisation Studies may contribute information included within Periodic Safety Update Reports (PSURs) and Periodic Benefit-Risk Evaluation Reports (PBRERs).

Relevant findings may include:

• cumulative medicine exposure;
• utilisation trends;
• changes in prescribing practice;
• use in populations of interest;
• impact of regulatory interventions.

These data support ongoing assessment of the medicinal product throughout its lifecycle.

Supporting Regulatory Referrals

During regulatory referral procedures, authorities frequently require information describing how medicines are used under routine clinical practice.

Drug Utilisation Studies may provide evidence regarding:

• utilisation before regulatory action;
• utilisation after regulatory action;
• prescribing compliance;
• implementation of new restrictions;
• geographical variation;
• changes in patient populations.

This information supports evidence-based regulatory recommendations.

Supporting Pharmacovigilance Inspections

Inspectors increasingly expect Marketing Authorisation Holders to demonstrate that Drug Utilisation Studies have been designed, conducted and interpreted according to recognised scientific principles.

Inspection activities may review:

• study protocols;
• analytical plans;
• database selection;
• quality management;
• study reports;
• regulatory commitments;
• integration with the Risk Management Plan.

Robust governance of Drug Utilisation Studies strengthens inspection readiness and demonstrates the maturity of the pharmacovigilance system.

Supporting Public Health

The value of Drug Utilisation Studies extends beyond regulatory pharmacovigilance.

Study findings may contribute to:

• clinical guideline development;
• antimicrobial stewardship;
• medicine optimisation;
• healthcare planning;
• reimbursement decisions;
• public health policy;
• equitable access to medicines.

Consequently, Drug Utilisation Studies support both regulatory science and broader healthcare improvement.

A Foundation for Evidence-Based Pharmacovigilance

Drug Utilisation Studies provide the evidence needed to understand how medicines are used in the real world. This information strengthens the interpretation of safety data, supports regulatory decision-making and improves the effectiveness of pharmacovigilance activities throughout the medicinal product lifecycle.

Rather than functioning as isolated observational studies, Drug Utilisation Studies should be regarded as foundational components of evidence-based pharmacovigilance that connect medicine utilisation with risk management, benefit-risk assessment and public health.

Scientific Foundation

Drug Utilisation Studies contribute to almost every major pharmacovigilance activity by providing objective evidence regarding real-world medicine use. Their integration with Risk Management Plans, signal management, benefit-risk assessment, Post-Authorisation Safety Studies, risk minimisation measures, periodic safety reporting and regulatory decision-making enables Marketing Authorisation Holders and regulatory authorities to interpret safety data within the context of routine clinical practice and continually improve the safe use of medicines.

Strengths of Drug Utilisation Studies

Drug Utilisation Studies have become an essential component of pharmacoepidemiology and pharmacovigilance because they provide objective evidence describing how medicines are used in routine clinical practice. Their principal strength lies in bridging the gap between regulatory approval and real-world medicine use, enabling investigators to understand prescribing behaviour, treatment patterns and healthcare practice across large populations.

Unlike controlled clinical trials, Drug Utilisation Studies evaluate medicines as they are prescribed and used in everyday healthcare. This provides valuable insights into medicine utilisation throughout the product lifecycle and supports evidence-based regulatory and public health decision-making.

Reflecting Real-World Clinical Practice

One of the greatest strengths of Drug Utilisation Studies is their ability to describe medicine use under routine clinical conditions.

These studies include patients who would often be excluded from clinical trials, such as those with:

• multiple comorbidities;
• concomitant medicines;
• advanced age;
• chronic disease;
• complex treatment pathways.

Consequently, Drug Utilisation Studies provide a more representative picture of medicine use within everyday healthcare.

Large and Representative Populations

Many Drug Utilisation Studies utilise national healthcare databases, administrative claims databases or Electronic Health Records containing information on millions of patients.

Large study populations enable investigators to:

• describe uncommon prescribing patterns;
• evaluate utilisation in special populations;
• examine geographical variation;
• study long-term trends;
• improve the precision of utilisation estimates.

Large populations also improve the generalisability of study findings.

Longitudinal Assessment of Medicine Use

Drug Utilisation Studies frequently follow medicine use over extended periods.

Longitudinal analyses allow investigators to evaluate:

• treatment initiation;
• treatment persistence;
• dose modification;
• medicine switching;
• changes in prescribing behaviour;
• long-term utilisation trends.

This lifecycle perspective is rarely achievable through pre-authorisation clinical trials.

Understanding Prescribing Behaviour

Drug Utilisation Studies provide unique insight into prescribing decisions made during routine clinical practice.

They may identify:

• variation between healthcare professionals;
• specialty-specific prescribing;
• regional differences;
• healthcare system influences;
• implementation of clinical guidelines;
• responses to regulatory interventions.

Understanding prescribing behaviour supports both pharmacovigilance and healthcare quality improvement.

Supporting Regulatory Decision-Making

Drug Utilisation Studies provide evidence that directly supports regulatory science.

Their findings may contribute to:

• Risk Management Plans;
• Post-Authorisation Safety Studies;
• effectiveness evaluation of risk minimisation measures;
• product information updates;
• benefit-risk assessments;
• regulatory referrals.

They therefore play an important role throughout the medicinal product lifecycle.

Supporting Risk Minimisation

Drug Utilisation Studies are particularly valuable when evaluating whether regulatory interventions influence clinical practice.

Studies may demonstrate:

• reduced prescribing in contraindicated populations;
• improved adherence to authorised indications;
• implementation of prescribing restrictions;
• changes following educational programmes;
• effectiveness of additional risk minimisation measures.

Objective utilisation data provide stronger evidence than assumptions regarding programme implementation.

Efficient Use of Existing Healthcare Data

Most contemporary Drug Utilisation Studies utilise routinely collected healthcare information.

Using existing databases offers several advantages:

• large sample sizes;
• reduced study costs;
• rapid study completion;
• long observation periods;
• minimal disruption to routine clinical practice.

Secondary healthcare data therefore provide an efficient foundation for observational medicine utilisation research.

Supporting Public Health

Drug Utilisation Studies contribute to healthcare planning beyond pharmacovigilance.

Their findings may support:

• medicine optimisation;
• antimicrobial stewardship;
• implementation of clinical guidelines;
• equitable access to medicines;
• healthcare resource planning;
• reimbursement policy.

The same evidence used for regulatory purposes may therefore contribute to broader public health objectives.

Complementing Other Evidence Sources

Drug Utilisation Studies do not replace clinical trials, spontaneous adverse event reporting or other pharmacoepidemiological investigations.

Instead, they complement these evidence sources by providing information regarding medicine exposure and utilisation within routine healthcare.

When interpreted alongside safety data, clinical evidence and benefit-risk assessments, Drug Utilisation Studies strengthen understanding of how medicines perform in real-world practice.

A Foundation for Real-World Evidence

As healthcare systems become increasingly digital, Drug Utilisation Studies continue to grow in importance.

Their ability to describe medicine use across diverse populations, healthcare settings and time periods makes them one of the most versatile tools available to pharmacovigilance professionals, regulators and healthcare researchers.

By generating reliable evidence regarding real-world medicine utilisation, Drug Utilisation Studies support safer prescribing, more effective risk management and continual improvement in the use of medicines throughout the healthcare system.

Scientific Foundation

Drug Utilisation Studies provide robust evidence describing real-world medicine use across large and representative populations. Their strengths include the ability to evaluate prescribing behaviour, treatment patterns, regulatory interventions and healthcare practice over extended periods while supporting pharmacovigilance, regulatory science, public health and evidence-based decision-making throughout the medicinal product lifecycle.

Limitations of Drug Utilisation Studies

Although Drug Utilisation Studies are powerful tools for understanding how medicines are used in routine clinical practice, they also have important methodological limitations. These limitations arise primarily because Drug Utilisation Studies are observational investigations that rely upon healthcare data originally collected for clinical care, reimbursement or administrative purposes rather than for research.

Recognising these limitations is essential for interpreting study findings appropriately. Experienced investigators do not regard limitations as reasons to avoid Drug Utilisation Studies but as factors that should be considered during study design, analysis and interpretation.

Observational Nature

Drug Utilisation Studies observe existing clinical practice without influencing treatment decisions.

Consequently, investigators cannot control:

• prescribing decisions;
• patient selection;
• treatment allocation;
• follow-up schedules;
• clinical management.

Unlike randomised clinical trials, observational studies cannot eliminate systematic differences between patients receiving different treatments.

Absence of Randomisation

Patients included in Drug Utilisation Studies are not randomly assigned to treatment.

Instead, prescribing decisions reflect routine clinical practice and may be influenced by:

• disease severity;
• physician preference;
• treatment guidelines;
• reimbursement policies;
• patient characteristics;
• healthcare system factors.

These differences complicate direct comparisons between treatment groups.

Confounding

Medicine utilisation is influenced by many factors that may also influence study outcomes.

Potential confounders include:

• age;
• sex;
• disease severity;
• comorbidities;
• socioeconomic status;
• healthcare access;
• concomitant medicines.

Failure to account for important confounders may result in misleading conclusions regarding medicine utilisation.

Confounding by Indication

One of the most important limitations in pharmacoepidemiology is confounding by indication.

Patients receive medicines because of their underlying disease, and that disease may influence healthcare utilisation, treatment duration, prescribing patterns and clinical outcomes.

Observed differences may therefore reflect characteristics of the disease rather than the medicine itself.

Investigators should consider this possibility during study design and interpretation.

Selection Bias

Study populations may not accurately represent all patients receiving the medicinal product.

Selection bias may arise because:

• certain healthcare providers contribute data;
• database coverage is incomplete;
• eligibility criteria exclude particular patient groups;
• patients move between healthcare systems.

Selection bias may reduce the generalisability of study findings.

Information Bias

Drug Utilisation Studies depend upon information recorded during routine healthcare.

Potential sources of information bias include:

• incomplete documentation;
• inaccurate coding;
• delayed data entry;
• inconsistent recording practices;
• missing clinical information.

The quality of study findings cannot exceed the quality of the underlying data.

Misclassification

Misclassification occurs when medicines, diagnoses or patient characteristics are recorded incorrectly.

Examples include:

• incorrect diagnostic coding;
• inaccurate medicine classification;
• errors in treatment duration;
• incorrect dosing information;
• incomplete recording of treatment discontinuation.

Misclassification may influence estimates of medicine utilisation and should be considered when interpreting study findings.

Missing Data

Healthcare databases frequently contain incomplete information.

Missing data may affect:

• diagnoses;
• laboratory results;
• treatment duration;
• prescribing indications;
• clinical outcomes;
• patient characteristics.

Investigators should evaluate both the extent of missing information and its potential impact on study validity.

Medicine Availability Does Not Equal Medicine Use

Many Drug Utilisation Studies rely upon prescription or dispensing records.

These databases demonstrate that a medicine was prescribed or supplied but cannot usually confirm:

• whether the prescription was filled;
• whether the medicine was taken;
• whether the medicine was taken correctly;
• long-term adherence.

Consequently, utilisation estimates should not automatically be interpreted as actual medicine consumption.

Database Limitations

Each healthcare database captures only part of the patient journey.

For example:

• prescribing databases may not include dispensing;
• dispensing databases may not include diagnoses;
• hospital databases may exclude community prescribing;
• primary care databases may not capture specialist treatment.

Combining multiple data sources may reduce these limitations but also introduces additional methodological complexity.

Limited Clinical Detail

Administrative databases frequently lack detailed clinical information.

Important variables may be unavailable, including:

• disease severity;
• laboratory values;
• clinical reasoning;
• treatment goals;
• lifestyle factors;
• patient preferences.

These limitations may restrict interpretation of prescribing behaviour.

Changing Healthcare Systems

Medicine utilisation changes over time because of:

• new clinical guidelines;
• regulatory actions;
• reimbursement changes;
• introduction of new medicines;
• evolving clinical practice.

Historical Drug Utilisation Studies should therefore be interpreted within the healthcare context in which they were conducted.

Generalisability

Findings from one healthcare system may not apply directly to another.

Differences in:

• prescribing practices;
• healthcare organisation;
• reimbursement models;
• medicine availability;
• regulatory requirements;
• patient populations

may limit the transferability of study findings between countries or healthcare settings.

Residual Uncertainty

Even after careful study design and analysis, some uncertainty remains.

Experienced investigators recognise that Drug Utilisation Studies describe patterns of medicine use rather than absolute truths.

Study findings should therefore be interpreted alongside evidence obtained from:

• clinical trials;
• spontaneous adverse event reports;
• Post-Authorisation Safety Studies;
• pharmacoepidemiological investigations;
• regulatory assessments;
• published scientific literature.

The strength of modern pharmacovigilance lies in integrating complementary evidence rather than relying upon a single study.

Limitations Do Not Reduce Scientific Value

The presence of methodological limitations does not diminish the importance of Drug Utilisation Studies.

Instead, awareness of these limitations enables investigators to:

• select appropriate study designs;
• choose suitable data sources;
• apply robust analytical methods;
• interpret findings cautiously;
• communicate uncertainty transparently.

When their strengths and limitations are fully understood, Drug Utilisation Studies remain one of the most valuable sources of real-world evidence supporting pharmacovigilance, regulatory science and public health.

Scientific Foundation

Drug Utilisation Studies are observational investigations that provide valuable information regarding real-world medicine use but are subject to important methodological limitations, including confounding, selection bias, information bias, incomplete data and database constraints. Recognising these limitations allows investigators to design more robust studies, interpret findings appropriately and integrate Drug Utilisation Study results with complementary sources of pharmacovigilance evidence.

Methodological Challenges in Drug Utilisation Studies

Drug Utilisation Studies are observational investigations conducted under routine clinical practice. Their strength lies in describing real-world medicine use, but this also introduces methodological challenges that must be recognised during study planning, analysis and interpretation.

Unlike randomised clinical trials, observational studies cannot fully control treatment allocation or patient characteristics. Consequently, investigators must identify potential sources of systematic error and implement appropriate measures to minimise their impact.

Methodological rigour therefore depends not on eliminating every source of bias, but on recognising important limitations, selecting appropriate study designs and interpreting findings within the context of the available evidence.

Bias in Observational Research

Bias is a systematic error that causes study findings to differ from the true pattern of medicine utilisation.

Unlike random error, which decreases as study size increases, systematic bias may persist regardless of the number of patients included.

The objective of study design is therefore to identify, minimise and transparently report potential sources of bias before interpreting study findings.

Selection Bias

Selection bias occurs when the study population differs systematically from the population that the investigator intended to study.

Potential causes include:

• incomplete database coverage;
• restrictive inclusion criteria;
• selective participation;
• referral patterns;
• healthcare access;
• regional differences.

Selection bias may reduce the representativeness of the study population and limit the generalisability of the findings.

Information Bias

Information bias arises when study variables are measured or recorded inaccurately.

Examples include:

• incomplete prescribing records;
• incorrect diagnostic coding;
• inaccurate treatment dates;
• inconsistent recording of treatment discontinuation;
• missing clinical information.

The impact of information bias depends upon both the extent of inaccurate recording and whether errors occur systematically.

Channeling Bias

Channeling bias occurs when particular medicines are preferentially prescribed to specific groups of patients because of perceived differences in safety, efficacy or clinical suitability.

For example, a newly introduced medicine may preferentially be prescribed to patients with more severe disease or to those who have failed previous therapies.

Observed utilisation patterns may therefore reflect prescribing decisions rather than inherent characteristics of the medicine.

Confounding

Confounding occurs when an external factor influences both medicine utilisation and the study outcome.

Examples of potential confounders include:

• age;
• disease severity;
• comorbidities;
• concomitant medicines;
• socioeconomic status;
• healthcare utilisation.

Appropriate study design and analytical methods should seek to minimise the influence of important confounding variables.

Confounding by Indication

Confounding by indication is one of the most important methodological challenges in pharmacoepidemiology.

Medicines are prescribed because patients have a particular disease or clinical indication. That indication may itself influence treatment patterns, healthcare utilisation and clinical outcomes.

Consequently, observed differences between treatment groups may reflect differences in the underlying disease rather than differences in the medicines themselves.

This form of confounding should always be considered when interpreting Drug Utilisation Studies.

Immortal Time Bias

Immortal time bias occurs when part of the observation period is incorrectly classified in a way that guarantees patients survive or remain event-free during that interval.

Improper definition of treatment initiation, exposure periods or follow-up may introduce this bias and produce misleading estimates of medicine utilisation or treatment persistence.

Careful definition of exposure windows and observation periods reduces the risk of immortal time bias.

Time-Window Bias

Time-window bias may occur when comparison groups have unequal opportunities for medicine exposure or follow-up.

Differences in observation periods may create apparent differences in utilisation that are attributable to study design rather than genuine clinical practice.

Consistent follow-up definitions improve comparability between study groups.

Exposure Misclassification

Accurate characterisation of medicine exposure is fundamental to every Drug Utilisation Study.

Exposure may be misclassified when:

• prescriptions are recorded incorrectly;
• dispensing records are incomplete;
• treatment discontinuation is not documented;
• medicines are obtained outside the captured healthcare system.

Exposure misclassification may distort estimates of medicine utilisation and treatment persistence.

Outcome Misclassification

Studies evaluating treatment pathways or healthcare utilisation may also misclassify important outcomes.

Examples include:

• incorrect diagnosis codes;
• inaccurate identification of treatment discontinuation;
• incomplete recording of medicine switching;
• inconsistent coding across healthcare providers.

Standardised outcome definitions improve study validity and reproducibility.

Missing Data

Incomplete information is a common feature of healthcare databases.

Investigators should evaluate:

• the extent of missing data;
• patterns of missingness;
• variables most affected;
• potential influence on study conclusions.

Transparent reporting of missing information enables readers to judge its potential impact.

Validation Studies

Validation studies assess whether database variables accurately represent the clinical concepts they are intended to measure.

Examples include validation of:

• diagnosis codes;
• prescribing records;
• exposure definitions;
• treatment discontinuation;
• clinical outcomes.

Validation strengthens confidence in both the data source and the resulting Drug Utilisation Study.

Sensitivity Analyses

Sensitivity analyses examine whether study conclusions remain stable when alternative assumptions or analytical methods are applied.

Examples include:

• alternative exposure definitions;
• revised inclusion criteria;
• different follow-up periods;
• subgroup analyses;
• alternative statistical approaches.

Consistent findings across multiple analyses increase confidence in the robustness of study conclusions.

Transparency in Reporting

Methodological challenges should never be concealed.

High-quality Drug Utilisation Studies clearly describe:

• study limitations;
• potential biases;
• assumptions;
• data quality issues;
• analytical decisions;
• remaining uncertainty.

Transparent reporting enables regulators, researchers and healthcare professionals to interpret findings appropriately.

Methodological Rigour Strengthens Scientific Confidence

Every observational study contains methodological challenges.

The objective is not to eliminate uncertainty completely but to design studies that recognise potential sources of bias, apply appropriate methodological safeguards and communicate remaining uncertainty honestly.

When these principles are followed, Drug Utilisation Studies provide reliable real-world evidence that supports pharmacovigilance, regulatory science and public health decision-making.

Scientific Foundation

Drug Utilisation Studies require careful consideration of methodological challenges, including bias, confounding, exposure misclassification, missing data and database limitations. Through appropriate study design, validation, sensitivity analyses and transparent reporting, investigators can minimise systematic error and generate scientifically robust evidence describing medicine utilisation in routine clinical practice.

Interpreting Drug Utilisation Study Results

Interpreting the findings of a Drug Utilisation Study requires considerably more than reviewing tables, graphs or statistical summaries. Every study should be interpreted within the context of its objectives, methodology, data source, healthcare environment and the limitations inherent in observational research.

Experienced reviewers recognise that Drug Utilisation Studies describe patterns of medicine use rather than establish universal truths about clinical practice. Their value lies in generating evidence that informs regulatory decisions, pharmacovigilance activities and healthcare policy when interpreted alongside complementary sources of evidence.

The interpretation of study findings should therefore be systematic, transparent and scientifically balanced.

Begin With the Research Question

Interpretation should always begin by returning to the original research question.

Investigators should ask:

• What question was the study designed to answer?
• Was the objective clearly defined?
• Was the selected study design appropriate?
• Did the available data adequately address the objective?

A statistically sophisticated analysis cannot compensate for an ill-defined research question.

The conclusions should answer the predefined objective rather than secondary questions that emerge after data analysis.

Evaluate the Study Population

The characteristics of the study population determine the applicability of the findings.

Important considerations include:

• inclusion criteria;
• exclusion criteria;
• patient demographics;
• disease characteristics;
• healthcare setting;
• geographical coverage;
• observation period.

Readers should consider whether the study population adequately represents the population to which the conclusions will be applied.

Consider the Data Source

Interpretation should account for the strengths and limitations of the underlying database.

Questions include:

• Does the database capture prescribing or dispensing?
• Are diagnoses available?
• Is longitudinal follow-up complete?
• How accurate are coding systems?
• Are important clinical variables missing?
• Are multiple healthcare settings represented?

Every database reflects only part of routine clinical practice.

Understanding these limitations is essential for appropriate interpretation.

Assess Data Quality

Before interpreting utilisation patterns, investigators should consider the quality of the underlying data.

Important aspects include:

• completeness;
• consistency;
• validity;
• missing information;
• duplicate records;
• coding accuracy.

Apparent utilisation patterns may occasionally reflect differences in data quality rather than genuine differences in clinical practice.

Distinguish Statistical Significance From Clinical Importance

Large healthcare databases frequently produce statistically significant differences that have little practical relevance.

Investigators should therefore distinguish between:

• statistical significance;
• clinical importance;
• regulatory relevance;
• public health impact.

A small numerical difference may have little effect on prescribing practice, whereas a modest change involving a widely used medicine may have substantial public health implications.

Interpretation should always consider the clinical context rather than statistical results alone.

Evaluate Consistency

Confidence in study findings increases when results remain consistent across:

• healthcare settings;
• geographical regions;
• patient subgroups;
• analytical methods;
• sensitivity analyses;
• independent studies.

Consistency strengthens scientific confidence but does not by itself establish causality.

Unexpected differences should prompt further investigation rather than immediate conclusions.

Consider Changes Over Time

Medicine utilisation evolves continuously.

Observed changes may result from:

• regulatory actions;
• publication of clinical guidelines;
• introduction of competing therapies;
• reimbursement changes;
• emerging safety information;
• changes in clinical practice.

Temporal trends should therefore be interpreted within their broader healthcare and regulatory context.

Interpret Findings Alongside Other Evidence

Drug Utilisation Studies provide one component of the pharmacovigilance evidence base.

Their findings should be considered together with:

• spontaneous adverse event reports;
• clinical trials;
• Post-Authorisation Safety Studies;
• pregnancy registries;
• Risk Management Plans;
• benefit-risk assessments;
• published scientific literature.

No single study should determine regulatory or clinical decisions in isolation.

Recognise Residual Uncertainty

Every Drug Utilisation Study contains some degree of uncertainty.

Residual uncertainty may arise from:

• observational study design;
• unmeasured confounding;
• incomplete follow-up;
• database limitations;
• changing clinical practice;
• residual bias.

Experienced investigators acknowledge this uncertainty explicitly rather than overstating the certainty of their conclusions.

Drawing Appropriate Conclusions

Study conclusions should remain closely aligned with the available evidence.

Appropriate conclusions:

• answer the original research question;
• acknowledge important limitations;
• avoid unsupported causal language;
• distinguish observed findings from interpretation;
• identify areas requiring further investigation.

Over-interpretation weakens scientific credibility and may lead to inappropriate regulatory or clinical decisions.

Communicating Findings

Drug Utilisation Study findings should be communicated clearly to their intended audience.

Regulators may require detailed methodological information.

Healthcare professionals may be more interested in implications for prescribing practice.

Public health authorities may focus on medicine utilisation at the population level.

Effective communication presents scientific findings accurately while ensuring that the conclusions remain understandable and relevant to decision-makers.

From Evidence to Decision-Making

The ultimate purpose of a Drug Utilisation Study is not to produce descriptive statistics but to support informed decision-making.

Study findings may influence:

• Risk Management Plans;
• Post-Authorisation Safety Studies;
• benefit-risk assessments;
• regulatory actions;
• healthcare policy;
• clinical guideline implementation;
• future research priorities.

The quality of these decisions depends upon the scientific quality of the study and the rigour with which its findings are interpreted.

Interpretation Requires Scientific Judgement

Interpreting Drug Utilisation Studies is an exercise in scientific judgement rather than simple statistical review.

Experienced pharmacoepidemiologists evaluate the totality of the evidence, recognise methodological limitations, understand the healthcare context and avoid drawing conclusions that extend beyond the available data.

This balanced approach enables Drug Utilisation Studies to contribute meaningfully to pharmacovigilance, regulatory science and evidence-based medicine.

Scientific Foundation

The interpretation of Drug Utilisation Studies requires integration of the study objectives, methodology, data quality, healthcare context and complementary pharmacovigilance evidence. Appropriate interpretation distinguishes statistical findings from clinical relevance, acknowledges residual uncertainty and ensures that regulatory and public health decisions are based upon the totality of the available evidence rather than isolated study results.

Inspection Perspective

Drug Utilisation Studies are increasingly reviewed during pharmacovigilance inspections because they frequently support important regulatory activities, including Risk Management Plans, Post-Authorisation Safety Studies, effectiveness evaluations of risk minimisation measures and post-authorisation regulatory commitments. Inspectors expect these studies to be scientifically justified, appropriately governed and capable of providing reliable evidence that supports pharmacovigilance decision-making.

Inspection activities therefore extend well beyond reviewing the final study report. Inspectors evaluate the complete lifecycle of the study, from the original regulatory question through protocol development, data source selection, study conduct, analysis, interpretation and implementation of the findings.

Inspection Objectives

When reviewing a Drug Utilisation Study, inspectors typically seek assurance that:

• the study addressed a clearly defined scientific or regulatory question;
• the methodology was appropriate for the study objectives;
• the selected data source was suitable;
• study governance was adequately documented;
• analyses were performed according to the approved protocol;
• conclusions were supported by the available evidence;
• findings were appropriately integrated into the pharmacovigilance system.

The objective is to determine whether the study provides reliable evidence that can support regulatory and public health decisions.

Scientific Justification

Inspectors commonly begin by reviewing the scientific rationale for conducting the Drug Utilisation Study.

Typical questions include:

• Why was the study required?
• Which regulatory or pharmacovigilance question was it intended to answer?
• Why was a Drug Utilisation Study selected instead of another study design?
• Was the objective aligned with the Risk Management Plan or regulatory commitment?

A clearly documented rationale demonstrates that the study was designed to answer a meaningful scientific question rather than simply fulfil an administrative requirement.

Protocol Review

The study protocol is one of the most important inspection documents.

Inspectors may review whether the protocol clearly defines:

• study objectives;
• study design;
• target population;
• inclusion and exclusion criteria;
• exposure definitions;
• study variables;
• endpoints;
• analytical methods;
• quality assurance activities.

The protocol should demonstrate that the study was planned prospectively and according to recognised scientific principles.

Data Source Selection

Inspectors evaluate whether the selected database or databases were appropriate for the study objectives.

They may consider:

• population coverage;
• completeness of exposure data;
• availability of clinical variables;
• duration of follow-up;
• coding systems;
• validation status;
• known limitations.

The choice of data source should be scientifically justified and documented.

Data Quality and Governance

Reliable evidence depends upon reliable data.

Inspectors may review:

• data acquisition procedures;
• quality control processes;
• data cleaning methods;
• validation activities;
• management of missing data;
• database version control;
• audit trails where applicable.

Strong data governance increases confidence in study findings.

Study Conduct

Inspection activities may assess whether the Drug Utilisation Study was conducted according to the approved protocol.

Examples include reviewing:

• protocol deviations;
• amendments;
• study milestones;
• quality management activities;
• documentation of analytical decisions;
• management of unexpected issues.

Any important deviations should be justified and documented appropriately.

Interpretation of Findings

Inspectors evaluate whether the study conclusions are supported by the available evidence.

They commonly assess whether investigators:

• distinguished observations from interpretation;
• acknowledged study limitations;
• considered potential biases;
• avoided unsupported causal conclusions;
• interpreted findings within the healthcare context.

Balanced interpretation is regarded as an important indicator of scientific quality.

Integration With the Pharmacovigilance System

A Drug Utilisation Study should not exist in isolation.

Inspectors may examine whether study findings were incorporated into:

• Risk Management Plans;
• Periodic Safety Update Reports;
• Post-Authorisation Safety Studies;
• benefit-risk assessments;
• effectiveness evaluations;
• regulatory responses;
• internal governance processes.

The value of the study depends not only on its quality but also on how its findings influence pharmacovigilance activities.

Common Inspection Findings

Inspection observations relating to Drug Utilisation Studies frequently involve:

• poorly defined study objectives;
• inadequate scientific justification;
• inappropriate data source selection;
• insufficient documentation of analytical methods;
• incomplete consideration of bias and confounding;
• conclusions extending beyond the available evidence;
• weak study governance;
• failure to incorporate findings into pharmacovigilance activities.

Many of these findings reflect deficiencies in study planning or governance rather than problems with the observational methodology itself.

Inspection Readiness

Marketing Authorisation Holders should maintain Drug Utilisation Studies in a continuous state of inspection readiness.

This includes ensuring that:

• protocols remain available;
• study documentation is complete;
• analytical methods are reproducible;
• regulatory commitments are tracked;
• study reports are version controlled;
• governance activities are documented;
• study findings are reflected in relevant pharmacovigilance documents.

Inspection readiness should be an ongoing organisational process rather than an activity undertaken immediately before an inspection.

What Inspectors Ultimately Evaluate

Although inspectors review individual components of a Drug Utilisation Study, their primary objective is to determine whether the study represents scientifically credible evidence that supports the pharmacovigilance system.

Ultimately, inspectors seek evidence that the study:

• addressed an important regulatory question;
• employed an appropriate methodology;
• used suitable data sources;
• acknowledged methodological limitations;
• produced reliable and reproducible findings;
• informed pharmacovigilance decision-making.

A high-quality Drug Utilisation Study demonstrates not only methodological excellence but also meaningful contribution to the safe and effective use of medicines.

Inspection Insight

During pharmacovigilance inspections, Drug Utilisation Studies are evaluated as scientifically governed observational investigations that support regulatory decision-making. Inspectors expect Marketing Authorisation Holders to demonstrate a clear scientific rationale, robust methodology, appropriate data governance, balanced interpretation and effective integration of study findings into the wider pharmacovigilance system. The ultimate measure of quality is not the completion of the study itself, but the reliability of the evidence it generates and its contribution to protecting public health.

How an Experienced Pharmacoepidemiologist Thinks About Drug Utilisation Studies

Experienced pharmacoepidemiologists view Drug Utilisation Studies as scientific tools for understanding how medicines are used within complex healthcare systems. They recognise that medicine utilisation reflects the interaction of patients, healthcare professionals, healthcare organisations, regulatory requirements and clinical practice rather than the properties of the medicine alone.

Consequently, they approach every Drug Utilisation Study as an exercise in understanding healthcare behaviour, not simply measuring medicine exposure.

They Begin With the Decision That Must Be Made

Experienced pharmacoepidemiologists rarely begin by discussing databases or statistical methods.

Instead, they first ask:

• What decision will this study support?
• What uncertainty needs to be reduced?
• Which evidence is currently missing?
• Will the findings influence clinical practice, regulatory action or public health policy?

Only after defining the decision do they design the study.

They Define the Research Question Precisely

A well-defined research question is the foundation of every successful Drug Utilisation Study.

Experienced investigators ensure that the question clearly specifies:

• the population;
• the medicinal product;
• the healthcare setting;
• the observation period;
• the outcome of interest;
• the intended interpretation.

They recognise that poorly defined questions cannot be rescued by sophisticated analytical techniques.

They Think in Terms of Healthcare Systems

Medicine utilisation is rarely determined by a single factor.

Experienced pharmacoepidemiologists consider how prescribing may be influenced by:

• national healthcare systems;
• reimbursement policies;
• clinical guidelines;
• physician experience;
• medicine availability;
• patient access to care;
• regulatory interventions.

They recognise that utilisation patterns reflect the behaviour of healthcare systems as much as the behaviour of individual clinicians.

They Respect the Data

Experienced investigators understand that every database represents only one perspective on medicine utilisation.

Rather than asking:

"Which database is the largest?"

they ask:

• Which database best answers the research question?
• Which important variables are unavailable?
• Which patients are not represented?
• What assumptions are required to interpret these data?

They understand that database limitations shape the conclusions that can reasonably be drawn.

They Look Beyond Descriptive Statistics

Drug Utilisation Studies frequently generate extensive tables and graphs.

Experienced pharmacoepidemiologists look beyond numerical summaries and ask:

• Why did utilisation change?
• Which healthcare events explain the findings?
• Are observed differences clinically meaningful?
• Could methodological factors explain the results?
• Do the findings remain consistent across different analyses?

Their objective is explanation rather than description alone.

They Expect Uncertainty

Experienced investigators never expect observational studies to provide perfect answers.

Instead, they actively identify uncertainty arising from:

• incomplete data;
• confounding;
• healthcare variation;
• coding limitations;
• changing clinical practice;
• residual bias.

Rather than attempting to eliminate all uncertainty, they seek to understand its magnitude and likely impact on the study conclusions.

They Integrate Multiple Sources of Evidence

Drug Utilisation Studies rarely provide sufficient evidence in isolation.

Experienced pharmacoepidemiologists routinely integrate findings with:

• clinical trials;
• Post-Authorisation Safety Studies;
• spontaneous adverse event reporting;
• disease registries;
• benefit-risk assessments;
• published literature;
• regulatory guidance.

They recognise that confidence increases when different evidence sources tell a consistent scientific story.

They Avoid Over-Interpretation

Experienced investigators understand the limits of observational research.

They avoid conclusions that extend beyond the available evidence and distinguish carefully between:

• observation and interpretation;
• association and explanation;
• hypothesis generation and confirmation;
• statistical significance and clinical relevance.

Scientific credibility depends as much on acknowledging uncertainty as on presenting positive findings.

They Think About the Next Study

A completed Drug Utilisation Study rarely marks the end of an investigation.

Instead, experienced pharmacoepidemiologists ask:

• Which new questions have emerged?
• Which findings require confirmation?
• Are additional data sources needed?
• Should a PASS or comparative study follow?
• Does the Risk Management Plan require revision?

Each study contributes to an ongoing programme of evidence generation rather than functioning as an isolated project.

They Focus on Improving Healthcare

Ultimately, experienced pharmacoepidemiologists are less interested in producing reports than in improving the safe and effective use of medicines.

They measure success by whether a Drug Utilisation Study:

• improves understanding of medicine use;
• informs regulatory decisions;
• strengthens pharmacovigilance;
• supports rational prescribing;
• contributes to better patient care.

For them, Drug Utilisation Studies are tools for improving healthcare rather than simply fulfilling regulatory requirements.

The Pharmacoepidemiologist's Perspective

Experienced pharmacoepidemiologists understand that medicine utilisation is the visible expression of complex clinical and healthcare system interactions.

Their role is to transform routine healthcare data into scientifically credible evidence that informs pharmacovigilance, regulatory science and public health. They achieve this not through increasingly complex analyses alone, but through careful study design, thoughtful interpretation, intellectual honesty and a continual commitment to improving the quality of evidence available for decision-making.

Professional Reflection

Experienced pharmacoepidemiologists approach Drug Utilisation Studies with scientific curiosity, methodological discipline and intellectual humility. They recognise that the greatest value of these studies lies not in describing medicine use, but in generating reliable evidence that improves regulatory decisions, strengthens pharmacovigilance and ultimately contributes to safer and more effective patient care.

How an Experienced QPPV Thinks About Drug Utilisation Studies

An experienced Qualified Person Responsible for Pharmacovigilance (QPPV) views Drug Utilisation Studies as strategic pharmacovigilance tools that generate evidence supporting regulatory decision-making throughout the medicinal product lifecycle. While pharmacoepidemiologists focus on designing scientifically robust studies, the QPPV focuses on whether those studies answer important pharmacovigilance questions, support benefit-risk evaluation and strengthen the overall pharmacovigilance system.

For the QPPV, the value of a Drug Utilisation Study is determined not by the volume of data collected but by its contribution to protecting patients and improving regulatory decision-making.

They Begin With the Benefit-Risk Balance

Experienced QPPVs evaluate Drug Utilisation Studies within the context of the medicinal product's overall benefit-risk profile.

They ask:

• Why is this study required?
• Which uncertainty does it reduce?
• Which safety concern does it address?
• Will the findings influence benefit-risk evaluation?
• Could the study change regulatory decision-making?

Every Drug Utilisation Study should contribute to understanding how the medicine is used and whether its benefit-risk balance remains favourable under routine clinical practice.

They Think in Terms of Lifecycle Management

Drug Utilisation Studies are rarely isolated activities.

Experienced QPPVs consider where each study fits within the product lifecycle, including:

• initial marketing authorisation;
• implementation of the Risk Management Plan;
• post-authorisation commitments;
• periodic benefit-risk evaluation;
• regulatory variations;
• lifecycle extensions;
• emerging safety concerns.

Each study becomes one component of a continually evolving body of pharmacovigilance evidence.

They Integrate Drug Utilisation Studies With Risk Management

Experienced QPPVs ensure that Drug Utilisation Studies are fully integrated into the Risk Management System.

They consider whether study findings:

• confirm expected utilisation patterns;
• identify unexpected medicine use;
• support important identified risks;
• address important potential risks;
• reduce missing information;
• evaluate additional risk minimisation measures.

The study should strengthen the scientific foundation of the Risk Management Plan rather than exist as a separate research activity.

They Focus on Regulatory Questions

The QPPV evaluates Drug Utilisation Studies from a regulatory perspective.

Typical questions include:

• Has off-label prescribing increased?
• Are prescribing restrictions being followed?
• Have educational interventions changed clinical practice?
• Are medicines reaching unintended patient populations?
• Has a regulatory action altered utilisation?

These questions have direct implications for regulatory compliance and patient safety.

They Expect Governance Throughout the Study Lifecycle

Drug Utilisation Studies should operate within the organisation's quality management system.

Experienced QPPVs expect:

• clearly defined responsibilities;
• approved study protocols;
• documented methodological decisions;
• quality assurance activities;
• version-controlled study reports;
• formal change control;
• documented regulatory interactions.

Strong governance demonstrates that the study has been planned and conducted according to recognised scientific and regulatory standards.

They Look Beyond the Final Report

Completion of a Drug Utilisation Study is not the end of the process.

Experienced QPPVs ask:

• What did the study teach us?
• Should the Risk Management Plan be updated?
• Are further investigations required?
• Should risk minimisation measures be modified?
• Does the study affect future pharmacovigilance activities?

The greatest value of a Drug Utilisation Study lies in the decisions it informs rather than the report it produces.

They Integrate Multiple Evidence Streams

Experienced QPPVs never rely upon Drug Utilisation Studies in isolation.

Instead, they integrate findings with:

• spontaneous adverse event reports;
• signal management activities;
• Post-Authorisation Safety Studies;
• Periodic Safety Update Reports;
• literature surveillance;
• clinical trial data;
• benefit-risk assessments;
• regulatory feedback.

This integrated approach provides a comprehensive understanding of the medicinal product throughout its lifecycle.

They Prepare for Regulatory Scrutiny

Drug Utilisation Studies supporting regulatory commitments should always be inspection ready.

Experienced QPPVs ensure that they can demonstrate:

• the scientific rationale for the study;
• alignment with regulatory commitments;
• protocol compliance;
• data integrity;
• methodological robustness;
• balanced interpretation;
• implementation of study findings.

Inspection readiness is achieved through continuous governance rather than retrospective document preparation.

They View Every Study as an Opportunity to Improve the Pharmacovigilance System

Experienced QPPVs recognise that every Drug Utilisation Study generates knowledge extending beyond its immediate objectives.

Study findings may identify:

• opportunities to improve medicine use;
• weaknesses in risk minimisation measures;
• emerging prescribing trends;
• gaps in pharmacovigilance activities;
• priorities for future research.

Each completed study therefore contributes to the continual development of the pharmacovigilance system.

The QPPV Perspective

Ultimately, experienced QPPVs ask one overarching question:

"Has this Drug Utilisation Study generated reliable evidence that improves our understanding of medicine use and supports better pharmacovigilance and regulatory decisions throughout the product lifecycle?"

When the answer is yes, the study has fulfilled its purpose—not merely as an observational investigation, but as a strategic component of an evidence-based pharmacovigilance system.

Professional Reflection

Experienced QPPVs regard Drug Utilisation Studies as strategic evidence-generation activities that strengthen Risk Management Plans, support benefit-risk evaluation and improve regulatory decision-making. Through robust governance, integration with the wider pharmacovigilance system and continual reassessment of study findings, they ensure that Drug Utilisation Studies contribute meaningfully to patient safety and the responsible lifecycle management of medicinal products.

Key Takeaways

• Drug Utilisation Studies (DUS) are observational studies that describe how medicines are prescribed, dispensed and used under routine clinical practice.

• Drug Utilisation Studies bridge the gap between controlled clinical trials and real-world medicine use by providing evidence from routine healthcare settings.

• Every Drug Utilisation Study should begin with a clearly defined scientific or regulatory question that determines the study design, data source and analytical methods.

• Drug Utilisation Studies differ from Drug Consumption Studies by examining the clinical context of medicine use rather than simply quantifying medicine volume.

• Drug Utilisation Studies are a core methodology within pharmacoepidemiology but represent only one component of the broader discipline.

• Electronic Health Records, claims databases, dispensing databases, prescription databases and disease registries each provide complementary perspectives on medicine utilisation and should be selected according to the study objectives.

• Standardised classification systems and utilisation metrics, including the WHO Anatomical Therapeutic Chemical (ATC) Classification System and Defined Daily Dose (DDD), enable consistent measurement and comparison of medicine use across populations and healthcare systems.

• Drug Utilisation Studies support numerous pharmacovigilance activities, including Risk Management Plans, Post-Authorisation Safety Studies, signal management, benefit-risk assessment and the evaluation of risk minimisation measures.

• Drug Utilisation Studies are frequently used to evaluate prescribing behaviour, medicine exposure, adherence to authorised indications, off-label use, treatment persistence and the implementation of regulatory interventions.

• The quality of a Drug Utilisation Study depends upon appropriate study design, suitable data sources, clearly defined variables, robust analytical methods and transparent reporting.

• Observational studies are subject to important methodological challenges, including confounding, selection bias, information bias, exposure misclassification and incomplete data, all of which should be considered during interpretation.

• Statistical significance alone should not determine the importance of study findings. Clinical relevance, regulatory impact and public health implications are equally important.

• Drug Utilisation Study findings should always be interpreted alongside complementary evidence from clinical trials, spontaneous adverse event reports, PASS, benefit-risk assessments and published scientific literature.

• During pharmacovigilance inspections, regulators evaluate Drug Utilisation Studies as scientifically governed evidence-generation activities that support regulatory decision-making rather than as isolated research projects.

• Experienced pharmacoepidemiologists view Drug Utilisation Studies as tools for understanding healthcare systems and improving evidence-based medicine rather than simply describing prescribing patterns.

• Experienced QPPVs integrate Drug Utilisation Studies into the wider pharmacovigilance system, using their findings to strengthen Risk Management Plans, support benefit-risk evaluation and guide lifecycle management.

• The ultimate purpose of a Drug Utilisation Study is to generate reliable real-world evidence that improves regulatory decision-making, promotes rational medicine use and contributes to safer patient care throughout the medicinal product lifecycle.

Continue Reading

Drug Utilisation Studies form an important component of pharmacoepidemiology and modern pharmacovigilance. The following articles explore related concepts, methodologies and regulatory frameworks that complement Drug Utilisation Studies and provide a broader understanding of evidence generation throughout the medicinal product lifecycle.

Pharmacoepidemiology

• What Is Pharmacoepidemiology?
• Observational Studies in Pharmacoepidemiology
• Real-World Evidence in Pharmacovigilance
• Real-World Data in Pharmacovigilance
• Comparative Effectiveness Research
• Post-Authorisation Safety Studies (PASS)
• Post-Authorisation Efficacy Studies (PAES)

Risk Management

• What Is a Risk Management Plan (RMP)?
• GVP Module V: Risk Management Systems
• GVP Module VIII: Post-Authorisation Safety Studies
• GVP Module XVI: Risk Minimisation Measures
• Additional Risk Minimisation Measures
• Routine Risk Minimisation Measures
• Benefit-Risk Assessment in Pharmacovigilance

Drug Utilisation Methodology

• Drug Consumption Studies
• Cohort Studies
• Cross-Sectional Studies
• Longitudinal Studies
• Registry Studies
• Electronic Health Records
• Administrative Claims Databases
• Disease Registries
• Healthcare Databases in Pharmacoepidemiology

Drug Utilisation Metrics

• WHO Anatomical Therapeutic Chemical (ATC) Classification System
• Defined Daily Dose (DDD)
• Prescribed Daily Dose (PDD)
• Days of Therapy (DOT)
• Medication Possession Ratio (MPR)
• Proportion of Days Covered (PDC)
• Treatment Persistence and Adherence

Risk Evaluation

• Signal Detection
• Signal Validation
• Signal Assessment
• Emerging Safety Issues
• Signal Management
• Benefit-Risk Assessment
• Missing Information in Risk Management Plans

Regulatory Science

• European Medicines Agency (EMA)
• Good Pharmacovigilance Practices (GVP)
• ENCePP and Pharmacoepidemiology
• Qualified Person Responsible for Pharmacovigilance (QPPV)
• Pharmacovigilance System Master File (PSMF)
• Pharmacovigilance Inspections
• Pharmacovigilance Audits

Special Applications

• Pregnancy Prevention Programmes
• Educational Materials in Pharmacovigilance
• Patient Alert Cards
• Drug Utilisation Studies for Risk Minimisation
• Drug Utilisation Studies in Pregnancy
• Drug Utilisation Studies in Rare Diseases
• Drug Utilisation Studies in Oncology

Drug Utilisation Studies rarely exist as isolated investigations. They generate evidence that supports pharmacoepidemiology, pharmacovigilance, regulatory science, healthcare policy and public health. Exploring the related topics above provides a broader understanding of how medicine utilisation data contribute to the safe, effective and evidence-based use of medicinal products throughout their lifecycle.